KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Shares Outstanding (Diluted Average) (2018 - 2025)

Amneal Pharmaceuticals (AMRX) has 8 years of Shares Outstanding (Diluted Average) data on record, last reported at $324.8 million in Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) rose 5.12% year-over-year to $324.8 million; the TTM value through Dec 2025 reached $324.8 million, up 5.12%, while the annual FY2025 figure was $324.8 million, 5.12% up from the prior year.
  • Shares Outstanding (Diluted Average) reached $324.8 million in Q4 2025 per AMRX's latest filing, roughly flat from $323.7 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $324.8 million in Q4 2025 and bottomed at $149.9 million in Q1 2022.
  • Average Shares Outstanding (Diluted Average) over 5 years is $219.0 million, with a median of $157.3 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Diluted Average): dropped 0.88% in 2022, then skyrocketed 102.01% in 2024.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $151.8 million in 2021, then decreased by 0.58% to $150.9 million in 2022, then rose by 16.69% to $176.1 million in 2023, then surged by 75.42% to $309.0 million in 2024, then increased by 5.12% to $324.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Diluted Average) were $324.8 million in Q4 2025, $323.7 million in Q3 2025, and $323.2 million in Q2 2025.